Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data

Fig. 6

Immunotherapy response assessment. (A) Kaplan-Meier prognostic analysis in the IMvigor210 cohort. (B) The difference of riskscore between different immunotherapy responses in the IMvigor210 cohort. (C) The differential distribution of immunotherapy responses between high- and low- riskscore groups in the IMvigor210 cohort. (D) Kaplan-Meier prognostic analysis in the IMvigor210 cohort. (E) Kaplan-Meier prognostic analysis in stage I/II patients in the IMvigor210 cohort. (F) Kaplan-Meier prognostic analysis in stage III/IV patients in the GSE78220 dataset. (G) The difference of riskscore between different immunotherapy responses in the GSE78220 dataset. (H) The differential distribution of immunotherapy responses between high- and low- riskscore groups in the GSE78220 dataset. (I) Submap analysis indicated the association between the GRGs signature and immunotherapy responses. *p < 0.05;**p < 0.05<***p < 0.001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us